Severe Aortic Stenosis: How the Heart Team Decides Between TAVI and Open-Heart Surgery

If you or a loved one has been diagnosed with severe aortic stenosis - narrowing of the aortic valve - you're likely trying to understand two treatment paths: TAVI, a catheter-based procedure, and SAVR, traditional open-heart surgery. Both replace the diseased valve. This guide walks through how doctors actually choose between them: confirming the diagnosis, mapping the heart's anatomy in detail, and weighing age, surgical risk, and long-term valve planning together as a team.

Medically reviewed by: Dr. Arvind Singh, Senior Interventional and Structural Cardiologist and Dr. Sudhir Adalti, Senior Cardiothoracic & Vascular Surgeon, Apollo CVHF Hospital, Ahmedabad

Step 1: Confirming Severe, Symptomatic Aortic Stenosis

Aortic stenosis is most often caused by age-related valve calcification. Severity is confirmed by echocardiogram, using measures such as peak jet velocity, mean gradient, and valve area. Once stenosis is severe and causes symptoms - breathlessness, chest discomfort, dizziness, or fainting - outcomes without treatment are poor, and intervention is generally recommended.

Current guidance also supports earlier intervention in carefully selected asymptomatic patients with severe stenosis when procedural risk is low, particularly if there is evidence the left ventricle is starting to be affected (for example, a falling ejection fraction). This is a Heart Team decision, not a default.

Step 2: What Tests Are Usually Needed?

Before either procedure can be planned, a set of tests builds up a full picture of the heart and the patient's overall fitness for treatment:

Echocardiography establishes the severity and haemodynamic consequences of the stenosis (occasionally supplemented by transesophageal echocardiography for more detailed valve imaging); cardiac CT is particularly important for assessing TAVI suitability specifically, and also contributes useful information to surgical planning, though SAVR does not require the same depth of CT-based work-up that TAVI candidacy does.

Aortic annulus dimensions - to size the replacement valve
Coronary ostial height - how close the coronary arteries sit to the valve, relevant to the (rare) risk of coronary obstruction during TAVI
Aortic root anatomy and any aneurysmal disease
Calcium distribution and burden - asymmetric or bulky calcification affects both TAVI valve seating and surgical planning
Vascular access - femoral artery size and calcification, since most TAVI is done transfemorally; non-transfemoral access is considered when transfemoral access isn't feasible
Valve morphology - tricuspid vs. bicuspid, which materially affects the recommendation (below)

This imaging, alongside the echocardiogram, is what actually determines candidacy - not age or symptoms alone.

Test	What it tells the Heart Team
Echocardiogram	Severity of stenosis (jet velocity, mean gradient, valve area) and left ventricular function
ECG	Baseline heart rhythm and conduction system, relevant to later pacemaker risk
CT angiography	Valve anatomy, annulus sizing, coronary height, calcium distribution, and vascular access
Coronary assessment	Whether significant coronary artery disease is also present
Blood tests	Kidney function, haemoglobin, and other factors relevant to procedural planning
Clinical assessment	Symptoms, frailty, comorbidities, and life expectancy

Aortic annulus dimensions - to size the replacement valve

Coronary ostial height - how close the coronary arteries sit to the valve, relevant to the (rare) risk of coronary obstruction during TAVI

Aortic root anatomy and any aneurysmal disease

Calcium distribution and burden - asymmetric or bulky calcification affects both TAVI valve seating and surgical planning

Vascular access - femoral artery size and calcification, since most TAVI is done transfemorally; non-transfemoral access is considered when transfemoral access isn't feasible

Valve morphology - tricuspid vs. bicuspid, which materially affects the recommendation (below)

This imaging, alongside the echocardiogram, is what actually determines candidacy - not age or symptoms alone.

Step 3: The Heart Team Decision - Current Guideline Framework

Aortic valve treatment decisions are made by a Heart Team: a structural/interventional cardiologist and a cardiac surgeon assessing the same case together, incorporating formal surgical risk scoring (such as STS-PROM or EuroSCORE II) alongside anatomy, age, and life expectancy.
The 2025 ESC/EACTS valvular heart disease guideline sets out the current age- and risk-based framework for tricuspid aortic stenosis:

Patient profile	Guideline-preferred approach
?70 years, tricuspid valve, anatomically suitable	TAVI (Class I), regardless of surgical risk
<70 years, low surgical risk	SAVR
All other candidates	Individualised Heart Team decision, weighing anatomy, risk, life expectancy, and lifetime valve management
High surgical risk or inoperable, any age	TAVI
Bicuspid aortic valve	Anatomy is more complex (asymmetric calcification, elliptical annulus); TAVI is increasingly used in selected bicuspid patients with favourable anatomy, but generally carries a lower-strength recommendation than for tricuspid valves and requires closer anatomic scrutiny

This represents a meaningful shift from older frameworks: the age threshold favouring TAVI has moved down from 75 to 70, reflecting accumulating long-term trial data (including low-risk TAVI populations) rather than TAVI being reserved mainly for older or higher-risk patients.

Step 4: Choosing the Valve Type - The Trade-Off That Outlasts the Procedure

Once TAVI or SAVR is chosen as the approach, a separate but related decision is which type of valve to implant - because this affects the patient for years afterward, independent of which procedure was used to place it.

Valve type	Durability	Anticoagulation
Bioprosthetic (tissue) valve - used in TAVI and commonly in SAVR	Surgical bioprosthetic durability is well-characterised over decades; TAVI valve durability data is more established for older patients but still maturing for younger patients now increasingly receiving TAVI	Antithrombotic therapy after a tissue valve depends on the individual - presence of atrial fibrillation, prior thromboembolism, and other clinical indications for anticoagulation matter as much as the valve type itself
Mechanical valve - surgical only	Generally lasts the patient's lifetime	Requires lifelong warfarin, with regular monitoring, regardless of other risk factors

Because bioprosthetic valves can eventually degenerate, a valve-in-valve TAVI can often treat a failing surgical or transcatheter bioprosthesis without a second open operation - a "lifetime management" option worth discussing explicitly, since it affects how a younger patient might plan for a second intervention decades later. A mechanical valve avoids that reintervention question but commits the patient to lifelong anticoagulation.

Why SAVR Remains an Important Option, Not a Fallback

Surgery offers capabilities TAVI does not:

Concomitant procedures - coronary bypass, another valve repair/replacement, or aortic surgery can be performed in the same operation when needed.
Mechanical valve option - only available surgically, relevant for younger patients prioritising long-term durability over avoiding anticoagulation.
Direct surgical access for anatomy that is unfavourable for a transcatheter approach.

These are genuine clinical advantages, not simply the more invasive alternative to TAVI.

Procedure-Specific Risks

TAVI:

Vascular access complications
Permanent pacemaker requirement - more common with TAVI than SAVR, due to the valve's proximity to the heart's conduction tissue
Paravalvular leak
Stroke
Rarely, coronary obstruction during valve deployment

SAVR:

Risks related to cardiopulmonary bypass and general anaesthesia
Bleeding, infection, and a longer wound-healing period from the sternotomy
General cardiac surgery risks, including arrhythmia and, rarely, stroke or heart attack

Both carry a small but real risk of major complications; which is comparatively lower depends on the individual's risk score and anatomy rather than one procedure being universally safer.

Recovery: Two Different Timelines

Hospital discharge and return to normal activity are not the same timeline, for either procedure:

TAVI: many patients mobilise within a day and may be discharged within a few days, though this varies with age, frailty, and whether complications (such as needing a pacemaker) occur.
SAVR: hospital stay is typically longer, and the sternotomy requires a period of activity restriction (avoiding heavy lifting and pushing/pulling) while the breastbone heals - commonly several weeks, with gradual return to full activity guided by the surgical team.

In both cases, full recovery of energy and exercise tolerance can take longer than the hospital stay suggests, and is followed by cardiac rehabilitation where appropriate.

A Note from Dr. Arvind Singh and Dr. Sudhir Adalti

We evaluate these cases jointly - a structural cardiologist and a cardiothoracic surgeon reviewing the same CT and echocardiographic imaging together - because the decision genuinely depends on specifics: valve morphology, coronary height, calcium pattern, surgical risk score, and how a patient's age and life expectancy interact with valve durability. Age thresholds in current guidelines are a starting point for that discussion, not a substitute for it.

Apollo CVHF Hospital's Role in Aortic Valve Care

Apollo CVHF Hospital, Ahmedabad, brings structural cardiology and cardiac surgery together to evaluate and treat severe aortic stenosis, including TAVI/TAVR and surgical heart valve repair and replacement. Patients undergo joint evaluation by a structural cardiologist and cardiac surgeon before a treatment path is recommended.

Frequently Asked Questions

Does age alone decide whether I get TAVI or surgery?

No. Current guidelines use age 70 as a reference point for tricuspid aortic stenosis - TAVI is generally preferred at or above that age if anatomically suitable, and SAVR at lower surgical risk below it - but anatomy, surgical risk scoring, and life expectancy are assessed alongside age, and many patients fall into a range requiring individualised Heart Team judgment rather than a simple age rule.

If I get a tissue valve now, will I need another procedure later?

Possibly, since tissue valves can degenerate over time - this is more established for surgical bioprosthetic valves than for TAVI valves in younger patients, where long-term data are still accumulating. If a tissue valve does fail later, valve-in-valve TAVI can often treat it without another open operation.

Do I need to be on blood thinners for life after valve replacement?

Only certain, and only some patients. Mechanical valves (surgical only) require lifelong warfarin. Tissue valves generally don't require warfarin for the valve alone, but anticoagulation may still be needed for other reasons, such as atrial fibrillation - your cardiology team will base this on your full clinical picture, not the valve type alone.

Can TAVI be done in a bicuspid aortic valve?

Increasingly, yes, in selected patients with favourable anatomy - but bicuspid valves are anatomically more complex, and the recommendation for TAVI is generally weaker than for tricuspid valves. This makes detailed CT assessment particularly important in bicuspid disease.

Why would someone choose surgery if they qualify for TAVI?

Surgery allows other cardiac problems - such as significant coronary disease, another valve, or an aortic aneurysm - to be treated in the same operation, and it's the only route to a mechanical valve, which some younger patients prefer despite the anticoagulation requirement, in exchange for not needing a future reintervention.

Talking to a Specialist

If you've been diagnosed with aortic stenosis, or have symptoms such as breathlessness, chest discomfort, dizziness, or fainting, the appropriate next step is evaluation by a structural cardiologist and cardiac surgeon together, including echocardiography and CT imaging to determine anatomic suitability for each approach.

Medically reviewed by: Dr. Arvind Singh, , Senior Interventional and Structural Cardiologist, and Dr. Sudhir Adalti, , MS, MCh (CTVS), Senior Cardiothoracic & Vascular Surgeon, Apollo CVHF Hospital, Ahmedabad Last reviewed: September 2026 Last updated: September 2026

Disclaimer: This article is for general educational purposes and does not replace individualised medical advice. Treatment decisions should always be made in consultation with a qualified structural cardiologist and cardiac surgeon after a complete clinical evaluation.

Contact Us

Severe Aortic Stenosis: How the Heart Team Decides Between TAVI and Open-Heart Surgery